Navigation Links
New Way to Make Stem Cells?
Date:10/8/2009

Chemicals can do the work previously handled by genes, researchers find

THURSDAY, Oct. 8 (HealthDay News) -- Scientists say they can use chemicals to turn adult cells into patient-specific stem cells instead of relying on potentially cancer-causing genes.

U.S. researchers used chemicals to replace two of the four genes needed to turn adult cells into induced pluripotent stem cells (iPSCs), which are similar to embryonic stem cells.

"Stem cells have the greatest potential to dramatically change and improve the way we treat diseases," study lead author Justin K. Ichida, of the Harvard Stem Cell Institute, said in a news release. "We're very excited about our findings because it means that in the near future we should be able to make limitless supplies of stem cells and possibly replacement cells for patients with diseases."

Previous research identified four genes that can transform adult stem cells into iPS cells. The genes are delivered via a retrovirus that integrates into a cell's DNA. However, the DNA from the virus remains in the cells and, over time, may activate cancer-causing genes.

In this study, the researchers substituted small chemical molecules for two of the genes.

"This discovery is exciting because it demonstrates the feasibility of using chemicals to make safer patient-specific stem cells for transplantation medicine," Ichida said.

"One of the most important things we learned from this study is that with respect to molecular pathways, there may be several ways to convert one type of cell into another. By using a non-biased chemical screening approach, we uncovered a previously unknown way to make stem cells. The big challenge over the next decade will be to figure out how to make the right cells for disease treatment. This approach will be important for achieving that goal."

The study, funded by the New York Stem Cell Foundation, is published online Oct. 8 and in the Nov. 6 print issue of the journal Cell Stem Cell.

More information

The U.S. National Institutes of Health has more about stem cells.



-- Robert Preidt



SOURCE: New York Stem Cell Foundation, news release, Oct. 8, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... Abilene, Texas (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... out to world leaders in hopes of squashing a global crisis with solution to peace ... is guaranteed to work because the plan is given by the Creator Himself. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: